Kymera Therapeutics (KYMR) Accounts Payables (2019 - 2026)

Kymera Therapeutics (KYMR) has reported Accounts Payables for 8 consecutive years, with $12.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accounts Payables rose 25.1% year-over-year to $12.8 million; the TTM figure through Mar 2026 stood at $12.8 million (up 25.1% YoY), while the FY2025 annual figure was $4.0 million, down 32.96% from the prior year.
• Accounts Payables advanced to $12.8 million in Q1 2026 per KYMR's latest filing, from $4.0 million in the prior quarter.
• Across five years, Accounts Payables topped out at $12.8 million in Q1 2026 and bottomed at $2.4 million in Q2 2022.
• Historically, Accounts Payables has averaged $6.0 million across 5 years, with a median of $6.0 million in 2024.
• Annual changes were most pronounced in 2022 — Accounts Payables sank 70.97% — and 2023, when it soared 152.55%.
• Kymera Therapeutics' Accounts Payables stood at $4.3 million in 2022, then jumped by 63.21% to $7.1 million in 2023, then retreated by 15.35% to $6.0 million in 2024, then sank by 32.96% to $4.0 million in 2025, then jumped by 219.78% to $12.8 million in 2026.
• Business Quant data shows KYMR's Accounts Payables at $12.8 million in Q1 2026, $4.0 million in Q4 2025, and $5.5 million in Q3 2025.